GlassScriptPhysician profile
Samson Mebrahtu
NPI 1528030277
$3,139.92
in general payments reported to CMS, 2019-2025
42 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $306 · 2021: $710 · 2022: $841 · 2023: $343 · 2024: $34.79 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $273.06 | 2019-2022 | |
| Abbvie INC. | $270.00 | 2021-2025 | |
| Amgen INC. | $259.79 | 2021-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $235.81 | 2019-2024 | Ultomiris |
| Ucb, INC. | $177.35 | 2019-2023 | Briviact |
| Lundbeck LLC | $165.18 | 2019-2023 | Vyepti |
| Neurelis, INC. | $140.64 | 2021-2022 | |
| Eisai INC. | $137.30 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $121.69 | 2019-2021 | |
| Bausch Health US, LLC | $116.34 | 2019 | |
| Allergan, INC. | $112.37 | 2019-2021 | |
| Braemar Manufacturing, LLC | $108.17 | 2019 | |
| Argenx US, INC. | $78.58 | 2022-2023 | Vyvgart |
| Neurocrine Biosciences, INC. | $77.99 | 2020-2023 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $73.46 | 2021-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samson Mebrahtu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.